Integral Health Asset Management LLC Has $8.43 Million Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Integral Health Asset Management LLC lifted its holdings in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 87.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 150,000 shares of the medical research company's stock after purchasing an additional 70,000 shares during the quarter. Integral Health Asset Management LLC owned 0.08% of Exact Sciences worth $8,428,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Asset Planning Inc bought a new position in shares of Exact Sciences in the fourth quarter worth $40,000. AlphaQuest LLC lifted its holdings in shares of Exact Sciences by 22,825.0% in the fourth quarter. AlphaQuest LLC now owns 917 shares of the medical research company's stock valued at $52,000 after buying an additional 913 shares during the period. SBI Securities Co. Ltd. acquired a new stake in shares of Exact Sciences in the fourth quarter valued at $66,000. Ostrum Asset Management lifted its holdings in shares of Exact Sciences by 28.4% in the fourth quarter. Ostrum Asset Management now owns 2,382 shares of the medical research company's stock valued at $134,000 after buying an additional 527 shares during the period. Finally, Kieckhefer Group LLC acquired a new stake in shares of Exact Sciences in the fourth quarter valued at $188,000. Institutional investors own 88.82% of the company's stock.

Exact Sciences Stock Up 0.4%

NASDAQ:EXAS traded up $0.25 during trading hours on Friday, hitting $56.42. 3,197,591 shares of the company's stock traded hands, compared to its average volume of 2,606,994. The firm has a market cap of $10.64 billion, a P/E ratio of -10.13 and a beta of 0.92. Exact Sciences Co. has a twelve month low of $39.97 and a twelve month high of $72.83. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. The stock's fifty day moving average price is $46.37 and its two-hundred day moving average price is $52.19.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.16. The firm had revenue of $706.79 million for the quarter, compared to analyst estimates of $688.58 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. Exact Sciences's quarterly revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.60) earnings per share. On average, research analysts expect that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on EXAS shares. Barclays upped their price objective on Exact Sciences from $55.00 to $75.00 and gave the company an "overweight" rating in a report on Friday, May 2nd. Piper Sandler cut their price objective on Exact Sciences from $75.00 to $70.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Royal Bank of Canada upped their price objective on Exact Sciences from $52.00 to $54.00 and gave the company a "sector perform" rating in a report on Friday, May 2nd. Guggenheim restated a "buy" rating and issued a $60.00 price objective on shares of Exact Sciences in a report on Friday, April 11th. Finally, Bank of America cut their price objective on Exact Sciences from $72.00 to $65.00 and set a "buy" rating for the company in a report on Thursday, February 20th. Two equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $70.90.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.